Neglected Diseases - Drug Design and Discovery - page 358

in combination with, e.g., proguanil. A further advantage of combination therapy is prevention of
recrudescence, which in particular is a problem after treatment with artemisinin.
In this chapter, no attempt has been made to include all of the drugs or putative targets.
FURTHER READINGS
Azzouz, S., Maache, M., Garcia, R. G., and Osuma, A. 2005. Leishmanicidal activity of edelfosine, miltefosine
and ilmofosine. Pharmacology & Toxicology 96: 60-65.
Cook, G. C. and Zumla, A. I. (eds.). 2003. Manson's Tropical Diseases , 21st edn. London: Elsevier Science.
Croft, S. L., Barrett, M. P., and Urbina, J. A. 2005. Chemotherapy of trypanosomiasis and leishmaniasis. Trends
in Parasitology 21: 508-512.
Egan, T. J. 2004. Haemozoin formation as a target for the rational design of new antimalarials. Drug Design
Reviews—Online 1: 93-110.
Rosenthal, P. J. (ed.). 2001. Antimalarial Chemotherapy. Mechanism of Action, Resistance, and New Directions
in Drug Discovery . Totowa, NJ: Humana Press Inc.
Schlitzer, M. 2007. Malaria chemotherapeutics. ChemMedChem 2: 944-986.
Willcox, M., Bodeker, G. and Rasoanaivo, P. (ed.). 2004. Traditional Medicinal Plants and Malaria . Boca
Raton, FL: CRC Press.